Q32 Bio Inc. Common Stock (QTTB)
Stock · NASDAQ · Health Care
$7.5as of 10/16/2026
Price chart
Active signals
Support level
$5.57
Industry
Biotechnology: Pharmaceutical Preparations
QTTB Signal Track Record
How signals performed across all stocks →What QTTB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | +3.0% | 54% | September 30, 2026 |
| Bollinger Band Breakout | 22 | +5.6% | 55% | June 29, 2026 |
| Bollinger Band Breakdown | 18 | -15.0% | 33% | September 1, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -1.1% | 50% | November 24, 2025 |
| Any 20-session window (baseline) | +1.2% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About QTTB
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 22
- Website
- www.q32bio.com/
Fundamentals
- 1-day range
- $7.28$7.82
- Market cap
- $482.18M
- P/E (trailing)
- 7.95
- P/E (forward)
- -7.37
- EPS (trailing)
- $2.29
- Dividend yield
- —
- Beta
- 0.50
- Avg. volume
- 746.5K
52-week range
$1.91$23.57
Next earnings: November 6, 2025 · EPS estimate $-1.17
How Q32 Bio Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 10, 2026 · via SEC EDGAR / Finnhub
Operating Income$16.90M(31%)
Forecasts
6 analyst ratings
Buy 92%
Hold 8%
Sell 0%
1-year price forecast
High
$59
+686.7%
Median
$38
+406.7%
Low
$29
+286.7%
Q32 Bio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- QTTBQ32 Bio Inc. Common Stock$7.52▼ 3.22%Market cap $482.18MP/E 7.95$1.91$23.57
- EVMNEvommune Inc. Common Stock$5.17▼ 12.82%Market cap $481.93MP/E —$6.52$33.2
- EOLSEvolus Inc. Common Stock$7.1▼ 6.21%Market cap $487.98MP/E —$3.86$9.31
- AQSTAquestive Therapeutics Inc. Common Stock$3.78▼ 6.90%Market cap $491.83MP/E —$2.93$7.55
- OVIDOvid Therapeutics Inc. Common Stock$2.15▼ 4.87%Market cap $494.60MP/E —$1.18$3.11
- TENXTenax Therapeutics Inc. Common Stock$1.36▼ 9.93%Market cap $498.11MP/E —$1.31$19.4
- BIOABioAge Labs Inc. Common Stock$4.84▼ 9.53%Market cap $500.98MP/E —$5.04$25.96
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| QTTB Q32 Bio Inc. Common Stock | $482.18M | 7.95 | $7.52 | ▼ 3.22% | $1.91$23.57 |
| EVMN Evommune Inc. Common Stock | $481.93M | — | $5.17 | ▼ 12.82% | $6.52$33.2 |
| EOLS Evolus Inc. Common Stock | $487.98M | — | $7.1 | ▼ 6.21% | $3.86$9.31 |
| AQST Aquestive Therapeutics Inc. Common Stock | $491.83M | — | $3.78 | ▼ 6.90% | $2.93$7.55 |
| OVID Ovid Therapeutics Inc. Common Stock | $494.60M | — | $2.15 | ▼ 4.87% | $1.18$3.11 |
| TENX Tenax Therapeutics Inc. Common Stock | $498.11M | — | $1.36 | ▼ 9.93% | $1.31$19.4 |
| BIOA BioAge Labs Inc. Common Stock | $500.98M | — | $4.84 | ▼ 9.53% | $5.04$25.96 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Leerink Partners Initiates Coverage On Q32 Bio with Outperform Rating, Announces Price Target of $40benzinga · 10/12/2026
- This Biotech Had Good News for Hair Loss Sufferers. So Why Is the Stock Sinking?Yahoo · 10/1/2026
- Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026Yahoo · 9/30/2026
- Q32 Bio Announces Additional 36-Week Results And Initial Findings From The 16-Week Off-Drug Period From Part B Of The SIGNAL-AA Phase 2A Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA; Clinically Meaningful Efficacy Data Observed On Primary And Key Secondary Endpoints At Week 36; Robust Durability, Including Maintenance And Deepening Of ResponseBenzinga · 9/30/2026
- Jefferies Initiates Coverage On Q32 Bio with Buy Rating, Announces Price Target of $29Benzinga · 9/28/2026
- Q32 Bio: Durable Hair Regrowth Remains The GoalSeekingAlpha · 9/26/2026
- Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene EditingSeekingAlpha · 9/24/2026
- Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026Yahoo · 9/21/2026
- Q32 Bio Presents Additional 36-Week Data From Its Part B Of SIGNAL-AA Phase 2a Clinical Study Of Bempikibart At European Academy Of Dermatology And Venereology CongressBenzinga · 9/21/2026
Insider Activity
Insider Actions →Acquired
362.9K
Disposed
16.6K
- Violette Shelia M. · August 25, 2026 · Sale2.8K @ $16.56
- Kalowski Lee · August 25, 2026 · Sale4.0K @ $16.56
- Morrison Jodie Pope · August 25, 2026 · Sale9.8K @ $16.56
- Violette Shelia M. · July 16, 2026 · Grant37.5K
- Kalowski Lee · July 16, 2026 · Grant53.3K
- Morrison Jodie Pope · July 16, 2026 · Grant132.0K
- Isaac Manke · June 30, 2026 · Option Exercise53.5K @ $2.8
- Lundberg Sven Ante · June 12, 2026 · Grant10.8K
- Xu Diyong · June 12, 2026 · Grant10.8K
- GRAYZEL DAVID S. · June 12, 2026 · Grant10.8K
- Isaac Manke · June 12, 2026 · Grant10.8K
- Arthur Tzianabos · June 12, 2026 · Grant10.8K
- Mark T. Iwicki · June 12, 2026 · Grant10.8K
- Thistle Mary · June 12, 2026 · Grant10.8K
- Kathleen Laporte · June 12, 2026 · Grant10.8K
Institutional Ownership
March 31, 2026
- Total shares held
- 9.38M
- Total value held
- $58.95M
- Institutional holders
- 51
Top holders this quarter
- Unknown2.25M
- Unknown2.09M
- Unknown1.26M
- Unknown1.10M
- Unknown320.5K
- Unknown315.1K
- Unknown306.4K
- Unknown246.3K
- Unknown244.1K
- Unknown206.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Q32 Bio to Present Late‑Breaking Results of Bempikibart Trial at EADV Congress
Q32 Bio will present late‑breaking results from Part B of its SIGNAL‑AA Phase 2a study of Bempikibart for alopecia areata at the European Academy of Dermatology and Venereology Congress. The company also shared additional 36‑week data from the same study earlier in the congress. These updates provide new information on the drug’s safety and efficacy profile, which may influence market perception of the company’s pipeline.
Q32 Bio to Present Late‑Breaking Results of Bempikibart Trial at EADV Congress. Q32 Bio will present late‑breaking results from Part B of its SIGNAL‑AA Phase 2a study of Bempikibart for alopecia areata at the European Academy of Dermatology and Venereology Congress. The company also shared additional 36‑week data from the same study earlier in the congress. These updates provide new information on the drug’s safety and efficacy profile, which may influence market perception of the company’s pipeline.